| DRUG WATCH |
|
| Year : 2015 | Volume
: 47
| Issue : 2 | Page : 221-223 |
A case report on toxic epidermal necrolysis with etoricoxib
JS Kameshwari, Raju Devde
Department of Pharmacology, Adverse Drug Reaction Monitoring Center, Kakatiya Medical College, MGM Hospital, Warangal, Telangana, India
Correspondence Address:
Raju Devde
Department of Pharmacology, Adverse Drug Reaction Monitoring Center, Kakatiya Medical College, MGM Hospital, Warangal, Telangana
India
 Source of Support: Adverse Drug Reaction Monitoring Center,
Kakatiya Medical College, MGM Hospital, Warangal 506007
Telangna, India., Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.153436
Etoricoxib is a selective cyclo-oxygenase 2 (COX-2) enzyme inhibitor and is exploited for its analgesic activity in various disease conditions like osteoarthritis, gouty arthritis, acute pain including postoperative dental pain and primary dysmenorrhea, etc. Although highly efficacious in pain management the safety profile of this COX-2 inhibitor is yet to be established in a broader sense. Short-term clinical trials and postmarketing surveillance have shown a very rare incidence of very serious skin reactions like Steven Johnson syndrome or toxic epidermal necrolysis (TEN). In this case report, we summarize regarding a patient who developed TEN after treatment with etoricoxib for osteoarthritis that later resolved in 15 days after withdrawal and symptomatic treatment.
[FULL TEXT] [PDF]*
|
